Compound Summary
disopyramide
Compound Information
disopyramide
Compound Name: | disopyramide |
Compound CID: | 3114 |
Synonyms: | disopyramide 3737-09-5 Rythmodan Dicorantil Ritmodan More... |
Iupac Name: | 4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide |
InChI: | InChI=1S/C21H29N3O/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25) |
InChIKey: | UVTNFZQICZKOEM-UHFFFAOYSA-N |
Canonical Smiles: | CC(C)N(CCC(C1=CC=CC=C1)(C2=CC=CC=N2)C(=O)N)C(C)C |
Isomeric Smiles: | CC(C)N(CCC(C1=CC=CC=C1)(C2=CC=CC=N2)C(=O)N)C(C)C |
Molecular Weight: | 339.5 |
Molecular Formula: | C21H29N3O |
Compound Structure
2D Structure:
3D Structure:
Computed Properties
disopyramide
Molecular Weight: | 339.5 |
Molecular Formula: | C21H29N3O |
Hydrogen Bond Donor Count: | 1 |
Hydrogen Bond Acceptor Count: | 3 |
Rotatable Bond Count: | 8 |
Heavy Atom Count: | 25 |
Complexity: | 409 |
Synonyms
disopyramide
| disopyramide | disopyramide |
|---|---|
disopyramide |
3737-09-5 |
Rythmodan |
Dicorantil |
Ritmodan |
Disopiramida |
Searle 703 |
Disopyramidum |
Disopyramidum INN-Latin |
Disopiramida INN-Spanish |
SC 7031 |
SC-7031 |
gamma-Diisopropylamino-alpha-phenyl-alpha-(2-pyridyl)butyramide |
alpha-Diisopropylaminoethyl-alpha-phenylpyridine-2-acetamide |
H 3292 |
CHEMBL517 |
alpha-(2-(Diisopropylamino)ethyl)-alpha-phenyl-2-pyridineacetamide |
2-Pyridineacetamide, alpha-(2-(bis(1-methylethyl)amino)ethyl)-alpha-phenyl- |
CHEBI:4657 |
4-di(propan-2-yl)amino-2-phenyl-2-pyridin-2-ylbutanamide |
3737-09-5 (free base) |
MFCD00057366 |
4-(diisopropylamino)-2-phenyl-2-pyridin-2-ylbutanamide |
NCGC00015358-18 |
Isorythm |
Lispine |
DSSTox_CID_25536 |
DSSTox_RID_80938 |
DSSTox_GSID_45536 |
C21H29N3O |
4-(diisopropylamino)-2-phenyl-2-(pyridin-2-yl)butanamide |
Disopyramide Free Base |
4-bis(propan-2-yl)amino-2-phenyl-2-(pyridin-2-yl)butanamide |
2-Pyridineacetamide, .alpha.-2-bis(1-methylethyl)aminoethyl-.alpha.-phenyl- |
CAS-3737-09-5 |
Rythmodan P (TN) |
SR-01000003039 |
NCGC00016985-01 |
Prestwick_681 |
EINECS 223-110-2 |
Lispine|||Ritmilen |
Norpace (Salt/Mix) |
Spectrum_001008 |
Prestwick0_000266 |
Prestwick1_000266 |
Prestwick2_000266 |
Prestwick3_000266 |
Spectrum2_001033 |
Spectrum3_000404 |
Spectrum4_000524 |
Spectrum5_000943 |
D 7644 |
Lopac0_000402 |
Lopac0_000411 |
SCHEMBL16153 |
BSPBio_000112 |
BSPBio_001928 |
KBioGR_001127 |
KBioSS_001488 |
MLS002222242 |
DivK1c_000489 |
SPBio_001245 |
SPBio_002331 |
BPBio1_000124 |
GTPL7167 |
SC 13957 (Salt/Mix) |
DTXSID1045536 |
KBio1_000489 |
KBio2_001488 |
KBio2_004056 |
KBio2_006624 |
KBio3_001148 |
4-(Diisopropylamino)-2-phenyl-2-(2-pyridinyl)butanamide |
Disopyramide (JP17/USAN/INN) |
NINDS_000489 |
HMS1568F14 |
HMS2095F14 |
HMS2234G08 |
HMS3261A06 |
HMS3369O21 |
HMS3712F14 |
HMS3886E08 |
Disopyramide USAN:INN:BAN:JAN |
Disopyramide 1.0 mg/ml in Methanol |
Tox21_110727 |
Tox21_500402 |
2-Pyridineacetamide, alpha-(2-(diisopropylamino)ethyl)-alpha-phenyl- |
BDBM50028893 |
NSC791109 |
s5490 |
AKOS015894712 |
Tox21_110727_1 |
CCG-204495 |
DB00280 |
LP00402 |
MCULE-8866988334 |
NSC-791109 |
SDCCGSBI-0050388.P006 |
IDI1_000489 |
NCGC00015358-04 |
NCGC00015358-05 |
NCGC00015358-06 |
NCGC00015358-08 |
NCGC00015358-09 |
NCGC00015358-10 |
NCGC00015358-11 |
NCGC00015358-12 |
NCGC00015358-13 |
NCGC00015358-14 |
NCGC00015358-15 |
NCGC00015358-19 |
NCGC00015358-24 |
NCGC00015358-25 |
NCGC00093829-01 |
NCGC00093829-02 |
NCGC00093829-03 |
NCGC00261087-01 |
AC-16018 |
BS-17145 |
HY-12533 |
SMR001307254 |
SBI-0050388.P005 |
AB00053462 |
CS-0011990 |
D2793 |
EU-0100402 |
FT-0667714 |
ST50411970 |
Y5028 |
C06965 |
D00303 |
H-3292 |
T70845 |
20509-EP2272972A1 |
20509-EP2272973A1 |
20509-EP2277872A1 |
20509-EP2314585A1 |
AB00053462_16 |
AB00053462_17 |
Q425120 |
SR-01000003039-3 |
4-Diisopropylamino-2-phenyl-2-(2-pyridyl)-butyramide |
BRD-A29734509-001-03-8 |
BRD-A29734509-011-02-9 |
BRD-A29734509-011-06-0 |
SR-01000003039-10 |
4-(Diisopropylamino)-2-phenyl-2-(2-pyridyl)butyramide |
Z2786051711 |
4-(Diisopropylamino)-2-phenyl-2-(2-pyridinyl)butanamide # |
4-bis(methylethyl)amino-2-phenyl-2-(2-pyridyl)butanamide |
Disopyramide, European Pharmacopoeia (EP) Reference Standard |
.alpha.-(2-(Diisopropylamino)ethyl)-.alpha.-phenyl-2-pyridineacetamide |
.gamma.-Diisopropylamino-.alpha.-phenyl-.alpha.-(2-pyridyl)butyramide |
2-Pyridineacetamide, .alpha.-2-(diisopropylamino)ethyl-.alpha.-phenyl- |
4-bis(propan-2-yl)amino-2-phenyl-2-(pyridin-2-yl)butanimidic acid |
racemic 2-phenyl-2-(2-pyridyl)-4-N,N-bis(1-methylethyl)aminobutanamide |
1216989-88-6 |
Experimental Data
disopyramide
| Species | Dose | Unit | Control(Avg days) | Treatment(Avg days) | Avg/Med Lifespan Change(%) | Control(Max days) | Treatment(Max days) | Max Lifespan Change(%) | Significant | Strain | Gender | PubMed | Avg/Med Lifespan Change tab |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Caenorhabditis elegans | 33.000000000000000 | umol/L | 8.000000000000000 | NS | N2 | 24134630 | Inactive |
Experimental Data Visualization
disopyramide
Statistics Data
disopyramide
| Species | Avg/Med Lifespan Change(%) | Max Lifespan Change(%) | Count Reference | Count Data point |
|---|---|---|---|---|
| Caenorhabditis elegans | 8.000000000000000 | 1 | 1 |
Statistics Data Visualization
disopyramide
